Cystic fibrosis (CF) is a single-gene disorder with insufficient treatment options and a target organ, the lung that is relatively easily accessible. Thus, it is not surprising that in the early ...

Gene therapy has shown potential in treating various genetic disorders, such as sickle cell anemia, cystic fibrosis, and certain types of cancer. Recombinant DNA technology has revolutionized vaccine ...

The CFTR Protein Distribution Core offers high-quality, full-length recombinant cystic fibrosis transmembrane conductance regulator (CFTR) proteins expressed in and purified from mammalian cells. Wild ...

The Gene Expression Core was founded in 1994 and promotes translational, multidisciplinary CF research by furnishing expertise concerning recombinant CFTR and other proteins relevant to CF disease ...

An explanation of the cause and effects of the genetic disorder cystic fibrosis and how it can be treated using gene therapy. There is a discussion about gene therapy which includes an interview ...

The new method presented here should provide new opportunities for AAV-mediated gene therapy for muscular dystrophies, hemophilia A and cystic fibrosis.

ReCode Therapeutics is set to secure up to $15m in additional funding from the Cystic Fibrosis Foundation to enhance its gene correction research programme. The initiative, conducted in ...

CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. An estimated 105,000 people have been diagnosed with CF across 94 countries, according to the CF ...

The company’s ‘AAV + Augmenter’ platform helps develop customised therapies for cystic fibrosis and other respiratory conditions. The combination is designed to achieve high gene expression ...